hydralazine has been researched along with Disease Exacerbation in 27 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced morbidity and mortality among black patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers." | 7.83 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. ( Bhatt, DL; Butler, J; Curtis, LH; Eapen, ZJ; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Khazanie, P; Liang, L; Peterson, ED; Yancy, CW, 2016) |
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 5.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| "Sixteen older persons free of known cardiovascular disease with the exception of hypertension had noninvasive tonometry and cardiac ultrasound to evaluate central augmentation index (AI) and diastolic function at baseline and after randomized, blinded administration of intravenous B-type natriuretic peptide (BNP) and hydralazine in a crossover design." | 5.17 | Left ventricular responses to acute changes in late systolic pressure augmentation in older adults. ( Eggleston, K; Hetzel, SJ; Mitchell, GF; Skalski, J; Sweitzer, NK; Velez, M, 2013) |
| "In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced morbidity and mortality among black patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers." | 3.83 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. ( Bhatt, DL; Butler, J; Curtis, LH; Eapen, ZJ; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Khazanie, P; Liang, L; Peterson, ED; Yancy, CW, 2016) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| " One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)." | 3.73 | Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| " After 10 weeks of treatment with benidipine (1, 3, and 5 mg/kg body weight, p." | 3.70 | Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis. ( Kawachi, H; Nakamura, T; Obata, JE; Onitsuka, M; Shimada, Y; Shimizu, F; Yoshida, Y, 2000) |
| "Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge." | 2.82 | Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? ( Bowlin, B; Finch, C; Hartmann, J; Reedus, J; Richardson, A; Sands, CW; Self, T; Tolley, E, 2016) |
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 1.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| "Renal fibrosis was increased 2." | 1.42 | A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. ( Bin, W; Cao, W; Hou, FF; Li, A; Su, Z; Wang, L; Wilcox, CS; Zhou, Z, 2015) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| "Aliskiren treatment almost completely suppressed angiotensin I and resulted in lower angiotensin II concentration than ramipril treatment." | 1.40 | Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading. ( Ayuzawa, N; Fujita, T; Ishizawa, K; Kawarazaki, W; Nagase, M; Takeuchi, M; Ueda, K; Yoshida, S, 2014) |
| "We report a case of posterior reversible encephalopathy syndrome (PRES) in a 73-yr-old woman with a history of uncontrolled hypertension who had recently discontinued one of her antihypertensive drugs; such cases are rare but pose a diagnostic challenge given the nonspecific nature of the clinical presentation." | 1.39 | Posterior reversible encephalopathy syndrome: 'a headache' on the AMU. ( Bholah, MH; Desai, P; Dunn, E, 2013) |
| "A 31-year-old woman developed bilateral posterior ischemic optic neuropathy and infarctions of the cerebral arterial border zones and spinal cord after correction of malignant hypertension." | 1.35 | Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. ( An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE, 2008) |
| "Captopril treatment significantly reduced cardiac mass (3." | 1.33 | Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. ( Gupta, S; Sen, S; Young, D, 2005) |
| " Here, we evaluated whether chronic administration of an NO donor, molsidomine, controlled systemic blood pressure and renal disease progression and prolonged survival in rats with renal mass reduction (RMR)." | 1.30 | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. ( Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, Y | 1 |
| Naito, H | 1 |
| Kitamori, K | 1 |
| Hashimoto, S | 1 |
| Asano, T | 1 |
| Nakajima, T | 1 |
| Hayashi, K | 1 |
| Shimokawa, T | 1 |
| Yamagata, M | 1 |
| Yoneda, K | 1 |
| Sweitzer, NK | 1 |
| Hetzel, SJ | 1 |
| Skalski, J | 1 |
| Velez, M | 1 |
| Eggleston, K | 1 |
| Mitchell, GF | 1 |
| Desai, P | 1 |
| Bholah, MH | 1 |
| Dunn, E | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Yoshida, S | 1 |
| Ishizawa, K | 1 |
| Ayuzawa, N | 1 |
| Ueda, K | 1 |
| Takeuchi, M | 1 |
| Kawarazaki, W | 1 |
| Fujita, T | 1 |
| Nagase, M | 1 |
| Cao, W | 1 |
| Li, A | 1 |
| Wang, L | 1 |
| Zhou, Z | 1 |
| Su, Z | 1 |
| Bin, W | 1 |
| Wilcox, CS | 1 |
| Hou, FF | 1 |
| Ueda, M | 1 |
| Uchimura, K | 1 |
| Narita, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 1 |
| Morinaga, J | 1 |
| Hayata, M | 1 |
| Kakizoe, Y | 1 |
| Adachi, M | 1 |
| Miyoshi, T | 1 |
| Shiraishi, N | 1 |
| Kadowaki, D | 1 |
| Sakai, Y | 1 |
| Mukoyama, M | 1 |
| Kitamura, K | 1 |
| Khazanie, P | 1 |
| Liang, L | 1 |
| Curtis, LH | 1 |
| Butler, J | 1 |
| Eapen, ZJ | 1 |
| Heidenreich, PA | 1 |
| Bhatt, DL | 1 |
| Peterson, ED | 1 |
| Yancy, CW | 2 |
| Fonarow, GC | 1 |
| Hernandez, AF | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Richardson, A | 1 |
| Tolley, E | 1 |
| Hartmann, J | 1 |
| Reedus, J | 1 |
| Bowlin, B | 1 |
| Finch, C | 1 |
| Sands, CW | 1 |
| Self, T | 1 |
| Tampe, B | 1 |
| Steinle, U | 1 |
| Tampe, D | 1 |
| Carstens, JL | 1 |
| Korsten, P | 1 |
| Zeisberg, EM | 1 |
| Müller, GA | 1 |
| Kalluri, R | 1 |
| Zeisberg, M | 1 |
| Stewart, GC | 1 |
| Kittleson, MM | 1 |
| Patel, PC | 1 |
| Cowger, JA | 1 |
| Patel, CB | 1 |
| Mountis, MM | 1 |
| Johnson, FL | 1 |
| Guglin, ME | 1 |
| Rame, JE | 1 |
| Teuteberg, JJ | 1 |
| Stevenson, LW | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Choi, JH | 1 |
| Choi, KD | 1 |
| Kim, JS | 1 |
| Kim, HJ | 1 |
| Lee, JE | 1 |
| An, SJ | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Shah, RM | 1 |
| Singh, M | 1 |
| Bhuriya, R | 1 |
| Molnar, J | 1 |
| Arora, RR | 1 |
| Khosla, S | 1 |
| Grisk, O | 1 |
| Rose, HJ | 1 |
| Lorenz, G | 1 |
| Rettig, R | 1 |
| Gupta, S | 1 |
| Young, D | 1 |
| Sen, S | 1 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 2 |
| Shimizu, F | 2 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Baumann, M | 1 |
| Janssen, BJ | 1 |
| Hermans, JJ | 1 |
| Peutz-Kootstra, C | 1 |
| Witzke, O | 1 |
| Smits, JF | 1 |
| Struijker Boudier, HA | 1 |
| Echols, MR | 1 |
| Suganuma, E | 1 |
| Babaev, VR | 1 |
| Motojima, M | 1 |
| Zuo, Y | 1 |
| Ayabe, N | 1 |
| Fogo, AB | 1 |
| Ichikawa, I | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Kon, V | 1 |
| Bhabra, MS | 1 |
| Hopkinson, DN | 1 |
| Shaw, TE | 1 |
| Hooper, TL | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Noris, M | 1 |
| Corna, D | 1 |
| Benedetti, G | 1 |
| Bruzzi, I | 1 |
| Todeschini, M | 1 |
| Remuzzi, G | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Nakamura, T | 1 |
| Obata, JE | 1 |
| Onitsuka, M | 1 |
| Shimada, Y | 1 |
| Yoshida, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Aortic Impedance on Myocardial Relaxation[NCT00204984] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydralazine and Disease Exacerbation
| Article | Year |
|---|---|
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
Favorable effects of vasodilators on left ventricular remodeling in asymptomatic patients with chronic moderate-severe aortic regurgitation and normal ejection fraction: a meta-analysis of clinical trials.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aortic Valve Insufficiency; Calci | 2012 |
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
Topics: Black or African American; Disease Progression; Drug Combinations; Endothelium, Vascular; Genetic Pr | 2006 |
2 trials available for hydralazine and Disease Exacerbation
| Article | Year |
|---|---|
Left ventricular responses to acute changes in late systolic pressure augmentation in older adults.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Disease Progression; Dose-Respons | 2013 |
Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
22 other studies available for hydralazine and Disease Exacerbation
| Article | Year |
|---|---|
The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive Agents; Blood Pre | 2020 |
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi | 2021 |
Posterior reversible encephalopathy syndrome: 'a headache' on the AMU.
Topics: Aged; Antihypertensive Agents; Brain Edema; Disease Progression; Female; Headache; Humans; Hydralazi | 2013 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Topics: Albuminuria; Amides; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiot | 2014 |
A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.
Topics: Analysis of Variance; Animals; Blotting, Western; Brain; Disease Models, Animal; Disease Progression | 2015 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Disease Progression; Drug Combinations; Female; Gu | 2016 |
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; D | 2017 |
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2016 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; C | 2008 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Sympathetic-renal interaction in chronic arterial pressure control.
Topics: Animals; Animals, Newborn; Arteriosclerosis; Blood Pressure; Body Weight; Creatinine; Crosses, Genet | 2002 |
Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Disease | 2005 |
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy | 2005 |
Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.
Topics: Age Factors; Aging; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; C | 2007 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
Attenuation of lung graft reperfusion injury by a nitric oxide donor.
Topics: Animals; Cardioplegic Solutions; Disease Models, Animal; Disease Progression; Hemodynamics; Hydralaz | 1997 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease | 1999 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Benidipine, a long-acting calcium-channel blocker, prevents the progression to end-stage renal failure in a rat mesangioproliferative glomerulonephritis.
Topics: Actins; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Creatinine; Dihydropyridines | 2000 |